LIVANOVA PLC (LIVN)
Health Care · Medical Devices · NASDAQ
LivaNova is a medical device company specializing in advanced therapies for cardiac surgery and neurological disorders, including epilepsy and sleep apnea.
What LIVANOVA PLC does
LivaNova PLC is a medical technology company focused on cardiovascular and neuromodulation solutions. The company develops and markets devices for cardiac surgery, such as cardiopulmonary bypass systems, as well as neuromodulation therapies for the treatment of drug-resistant epilepsy and obstructive sleep apnea.
Themes: cardiovascular surgery, neuromodulation, epilepsy treatment, sleep apnea therapy
Fundamentals
- Price$78.44 as of 2026-10-21 close
- Market cap$4.3B as of 2026-07-29 (share count; price 2026-10-21)
- 1-year return+43.4% 2025-10-21 close $54.71 → 2026-10-21 close $78.44
- P/E23.14 as of 2026-10-21
- Net margin-17.5% FY2025, SEC XBRL
- Gross margin+67.7% FY2025, SEC XBRL
- ROE-20.2% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.22 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+10.7% FY2025, SEC XBRL
- Revenue CAGR (3y)+10.8% SEC XBRL
- Beta0.94 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How LIVN compares in its sector
- price-to-earnings ratiomiddle range 181 covered Health Care peers, as of 2026-10-21
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
LIVN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
57.0 #346 of 1,265 scored · #52 of 145 in Health Care
Trend 75th (a "golden cross" — its 50-day average is above its 200-day) and financial health 71st (debt to equity 0.2, free cash flow margin 12.5%); weakest is capital return (32nd, consecutive years of dividend increases 0 years, net share count bought back over the year 0.1).
Scores as of 21 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $391M | $274M | $49M | $109M | $1.93 | $67M† | $32M† |
| Q1 FY2026 2026-03-31 | $362M | $244M | $41M | $22M | $0.40 | $15M | $14M |
| Q4 FY2025 2025-12-31 | $361M† | $240M† | $43M† | $31M† | $0.56† | $82M† | $32M† |
| Q3 FY2025 2025-09-30 | $358M | $245M | $54M | $27M | $0.49 | $85M† | $23M† |
| Q2 FY2025 2025-06-30 | $353M | $239M | $54M | $27M | $0.50 | $63M† | $15M† |
| Q1 FY2025 2025-03-31 | $317M | $216M | $49M | -$327M | -$6.01 | $24M | $11M |
| Q4 FY2024 2024-12-31 | $322M† | $214M† | $37M† | $56M† | $1.03† | $79M† | $10M† |
| Q3 FY2024 2024-09-30 | $318M | $221M | $36M | $33M | $0.60 | $51M† | $18M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$517M
- Total debt$290M borrowings only; leases excluded
- Net debt-$227M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How LIVANOVA PLC looks technically
LIVANOVA PLC (LIVN) is trading 8.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 298 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It made a new 20-day high about 2 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 8.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $78.52 | $78.52 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $72.13 | $72.13 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 27 calendar days ago — the swings before that are what the structure reading is measured on | 27 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 298 trading days ago — a "golden cross", a bullish long-term signal | 298 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($74.23 to $81.25) — its "stochastic" reading is 60 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 60.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $85.76 | $85.76 |
|---|---|---|
| From the 52-week high | it is 8.5% below its 52-week high (its highest price of the past year) | -8.5% |
| Above the 52-week low | it is 60.7% above its 52-week low (its lowest price of the past year) | +60.7% |
| Below the 52-week high | it is 8.5% below its highest point of the past year | 8.5% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 15 trading days ago | 15 sessions |
| All-time high | its highest closing price on record is $131.54 (set on 2018-09-12) | $131.54 |
| Given back of the 52-week move | over the past year its closes ranged ($49.57 to $85.33), and it has given back roughly a quarter of its rise from last year’s low — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $62.08 to $63.23. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.3% |
| From the all-time high | it is 40.4% below its all-time high | -40.4% |
| Nearest price level | it is trading 4.8% above a support level at $74.69 — a price it turned at three times since 2026-07-23, most recently on 2026-09-24. Since 2024-10-21 it has 17 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.8% |
| All-time low | its lowest closing price on record is $32.48 (set on 2025-04-09) | $32.48 |
| Above the all-time low | it is 141.5% above its all-time low | +141.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.23 between its high and its low — about 2.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.23 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $74.18 and $79.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $74.18 – $76.71 – $79.25 |
| Typical daily range (% of price) | its price moves about 2.8% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.8% |
| Stretch from the 200-day average | it is trading 2.8 daily ranges above its 200-day average price (8.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.86× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 6.4% below the previous close 54 sessions ago and has not traded back through the level it left behind at 85.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -6.4% |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.4 percentage points (the stock gained 0.3% while the market lost 0.1%) | +0.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 5.1 percentage points (the stock lost 1.8% while the market gained 3.3%) | -5.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 11.8 percentage points (the stock gained 21.6% while the market gained 9.8%) | +11.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 28.2 percentage points (the stock gained 43.4% while the market gained 15.2%) | +28.2% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.5% of the share price, which is taken to mean a barrier that gives way easily. | -1.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $71.72 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | +9.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $78.31 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +0.2% |
Price levels it has turned at before
LIVN last closed at $78.44 on 2026-10-21. Since 2024-10-21 it has turned at 17 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $74.69 | Support | 4.8% below the last close | turned there three times · 2026-07-23 to 2026-09-24 |
| $83.11 | Resistance | 6.0% above the last close | turned there twice · 2026-08-13 to 2026-09-03 |
| $71.46 | Support | 8.9% below the last close | turned there twice · 2026-02-26 to 2026-06-03 |
| $85.52 | Resistance | 9.0% above the last close | turned there twice · 2026-07-06 to 2026-08-04 |
| $67.98 | Support | 13.3% below the last close | turned there twice · 2026-02-02 to 2026-04-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Broke out to a new 20-day high · trendless / choppy (low ADX) · beating the market · Printed a bearish engulfing pair | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.64 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$90.55 range $75.00 – $105.00; median $93.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LIVN
- Consensus EPS estimate$1.06 next reporting period, as of 2026-10-17
- Estimate change, 30 days+$0.00243 (+0.2%) from $1.06, on 2026-09-12, 35-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant SNIA environmental legal liabilities and associated financial obligations.","Exposure to foreign exchange rate fluctuations affecting operating results.","Dependence on continuous innovation and successful clinical trial outcomes for new product regulatory approvals."]
What changed in the latest 10-Q
AI-assisted comparison of LIVN's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) adds: "with a registered office in Gloucester, England" in the Description of the Business section, replacing the older filing's "and is headquartered in London, England."
- Newer filing (2026-08-05) adds: "including through entry into supply agreements where possible" to the Macroeconomic Environment and Global Supply Chain section.
- Newer filing (2026-08-05) adds new sentences about IEEPA tariffs imposed in early 2025, the U.S. Supreme Court ruling the IEEPA tariffs unlawful, a refund process with U.S. Customs and Border Protection, and recognized net IEEPA tariff refunds impacting segment income by $5.8 million ($7.7 million reducing cost of sales and $1.9 million reducing net revenue) for the three and six months ended June 30, 2026.
- Newer filing (2026-08-05) adds: "The Company continues to monitor developments in global trade policy and assess potential implications for sourcing, pricing, and logistics."
- Removed:
- Older filing (2026-05-06) includes: "and is headquartered in London, England" in the Description of the Business section, which is removed in the newer filing.
- Older filing (2026-05-06) includes: "The Company continues to respond to such challenges." which is removed and replaced in the newer filing with "The Company continues to respond to such challenges, including through entry into supply agreements where possible."
- Reworded:
- Description of the Business: Newer filing (2026-08-05) changes "and is headquartered in London, England" to "with a registered office in Gloucester, England."
- Macroeconomic Environment and Global Supply Chain: Newer filing (2026-08-05) changes "The Company continues to respond to such challenges." to "The Company continues to respond to such challenges, including through entry into supply agreements where possible."
- Notes:
- The newer filing text ends mid-sentence at "For additional information, see “Part I," so any changes after that point are not assessable from the provided excerpts.
- The older filing text also ends at "For additional information, see “Part I," so no comparison beyond that point is possible from the provided excerpts.
Risk Factors
- Added:
- Newer filing (2026-08-05) covering six months ended June 30, 2026 includes results for both three and six months ended June 30, 2026, whereas older filing (2026-05-06) covered only the three months ended March 31, 2026.
- Newer filing includes comparative figures for the three and six months ended June 30, 2025.
- Newer filing references 'Operating results for the three and six months ended June 30, 2026' in the forward-looking statements discussion.
- Removed:
- Older filing (2026-05-06) referenced only 'Operating results for the three months ended March 31, 2026' in the forward-looking statements discussion.
- Older filing covered only the three months ended March 31, 2026 and the comparative three months ended March 31, 2025.
- Reworded:
- Newer filing changed the operating results reference from 'three months ended March 31, 2026' (older) to 'three and six months ended June 30, 2026' (newer).
- Notes:
- The provided section excerpts include full financial statements rather than only the Risk Factors section; the actual Risk Factors text may not be fully captured in either excerpt.
- Both excerpts appear heavily truncated at the end, potentially omitting subsequent risk factor disclosures.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 4 sells ($799783) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 6 sells ($1M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-10. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LIVN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
LIVN had 6,003,050 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
LIVN had 10.9% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.04 days to cover at the same settlement.
- Reported short interest (shares) 6,003,050
- Short interest (% of shares outstanding) 10.9%
- Prior settlement (shares) 5,375,448
- Reported change 11.68%
- Days to cover (reported) 8.04
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Edwards Lifesciences (EW)
- Getinge (GETI-B.ST)
- Terumo (4543.T)
- NeuroPace (NPCE)
- Inspire Medical Systems (INSP)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LIVN vs…
Frequently asked questions
What does LIVANOVA PLC (LIVN) do?
LivaNova PLC is a medical technology company focused on cardiovascular and neuromodulation solutions. The company develops and markets devices for cardiac surgery, such as cardiopulmonary bypass systems, as well as neuromodulation therapies for the treatment of drug-resistant epilepsy and obstructive sleep apnea.
What sector is LIVANOVA PLC (LIVN) in?
LIVANOVA PLC (LIVN) is classified in the Health Care sector. Its industry is Medical Devices. It trades on NASDAQ.
Who are LIVANOVA PLC's (LIVN) competitors?
Notable peers of LIVANOVA PLC (LIVN) include Medtronic, Edwards Lifesciences, Getinge (GETI-B.ST), Terumo (4543.T) and NeuroPace. This peer set is informational only — not financial advice.
Is LIVANOVA PLC (LIVN) overbought or oversold right now?
LIVANOVA PLC (LIVN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LIVN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.